Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study
Christoph U. Correll, Evan A. Stein, Christine Graham, et al.
Schizophrenia Bulletin (2022) Vol. 49, Iss. 2, pp. 454-463
Open Access | Times Cited: 17

Showing 17 citing articles:

Psychotropic Drug–Related Weight Gain and Its Treatment
Roger S. McIntyre, Angela T.H. Kwan, Joshua D. Rosenblat, et al.
American Journal of Psychiatry (2024) Vol. 181, Iss. 1, pp. 26-38
Closed Access | Times Cited: 42
Antipsychotic-Induced Weight Gain in Severe Mental Illness: Risk Factors and Special Considerations
Nicolette Stogios, Bailey Humber, Sri Mahavir Agarwal, et al.
Current Psychiatry Reports (2023) Vol. 25, Iss. 11, pp. 707-721
Closed Access | Times Cited: 32
Novel Compounds in the Treatment of Schizophrenia—A Selective Review
Eva-Maria Tsapakis, Kalliopi Diakaki, Apostolos Miliaras, et al.
Brain Sciences (2023) Vol. 13, Iss. 8, pp. 1193-1193
Open Access | Times Cited: 18
Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review
Marco Solmi, Alessandro Miola, Federico Capone, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 10, pp. 1249-1269
Closed Access | Times Cited: 5
Bibliometric Analysis of Antipsychotic-induced Metabolic Disorder from 2006 to 2021 Based on WoSCC Database
Zhihao Guo, Zi Zhang, Lu Li, et al.
Current Neuropharmacology (2025) Vol. 23, Iss. 4, pp. 439-457
Closed Access
Psychopharmakainduzierte Gewichtszunahme – sind Inkretine/Twinkretine eine Option?
Michael Paulzen
Der Nervenarzt (2025)
Closed Access
Schizophrenia and Related Psychoses

(2025), pp. 1-278
Closed Access
Insulin Resistance/Diabetes and Schizophrenia: Potential Shared Genetic Factors and Implications for Better Management of Patients with Schizophrenia
Chuanjun Zhuo, Qiuyu Zhang, Lina Wang, et al.
CNS Drugs (2023) Vol. 38, Iss. 1, pp. 33-44
Open Access | Times Cited: 12
Olanzapine, risperidone and ziprasidone differently affect lysosomal function and autophagy, reflecting their different metabolic risk in patients
Marco Pozzi, Chiara Vantaggiato, F Brivio, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia
Jonathan M. Meyer, Christoph U. Correll
CNS Drugs (2023) Vol. 37, Iss. 7, pp. 545-570
Open Access | Times Cited: 7
What Remains to Be Discovered in Schizophrenia Therapeutics: Contributions by Advancing the Molecular Mechanisms of Drugs for Psychosis and Schizophrenia
Christoph U. Correll, Massimo Tusconi, Mauro Giovanni Carta, et al.
Biomolecules (2024) Vol. 14, Iss. 8, pp. 906-906
Open Access | Times Cited: 2
Activation of the PERK-CHOP signaling pathway during endoplasmic reticulum stress contributes to olanzapine-induced dyslipidemia
Lu Liu, Lei Tang, Jiaming Luo, et al.
Acta Pharmacologica Sinica (2023) Vol. 45, Iss. 3, pp. 502-516
Closed Access | Times Cited: 4
Effects of Combined Therapy of Olanzapine and Samidorphan on Safety and Metabolic Parameters in Schizophrenia Patients: A Meta-Analysis
Zhenlei Peng, Qiyu Jia, Junxiong Mao, et al.
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 2295-2308
Open Access | Times Cited: 3
Promising translatable pharmacological interventions for body weight management in individuals with severe mental illness – a narrative review
Riddhita De, Femin Prasad, Nicolette Stogios, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 16, pp. 1823-1832
Closed Access | Times Cited: 3
Novel Compounds for the Treatment of Schizophrenia – A Narrative Review
Kalliopi Diakaki, Apostolos Miliaras, Eva-Maria Tsapakis, et al.
(2023)
Open Access | Times Cited: 2
Olanzapine-Samidorphan for Schizophrenia: A Systematic Review and Meta-Analysis
Dhyuti Gupta, Alok Singh
Indian Journal of Psychological Medicine (2023) Vol. 46, Iss. 1, pp. 14-23
Open Access | Times Cited: 2
Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment
Weronika Barbara Grywińska, Aleksandra Głowacka
Postępy Psychiatrii i Neurologii (2023) Vol. 32, Iss. 3, pp. 128-137
Open Access | Times Cited: 2
Page 1

Scroll to top